Vor Biopharma, Inc. (VOR)
| Market Cap | 789.79M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 22.26M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 11 |
| Last Price | $21.27 |
| Previous Close | $22.27 |
| Change ($) | -1.00 |
| Change (%) | -4.49% |
| Day's Open | 22.42 |
| Day's Range | 20.92 - 22.42 |
| Day's Volume | 71,639 |
| 52-Week Range | 18.11 - 63.62 |
CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targete...
Health Canada clears the CTA for VOR33 clinical trial
IND accepted for VOR33, Vor's lead eHSC product candidate for treatment of AML
CAMBRIDGE, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies f...
CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies f...
CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies fo...
Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced the prici...
Vor Biopharma, a Phase 1/2 biotech developing cell therapies for hematological diseases, filed on Friday with the SEC to raise up to $150 million in an initial public offering.
Vor Biopharma, Inc. has filed to go public with an IPO on the NASDAQ.
The FDA cleared an investigational new drug application for VOR33, an engineered stem cell therapy for the treatment of patients with acute myeloid leukemia who are at high risk for relapse, according t...
About VOR
Vor Biopharma is a clinical-stage cell therapy company combining a novel patient engineering approach with targeted therapies to provide a single company solution for patients suffering from hematological malignancies. For many patients, the only way to achieve durable remission or a cure is through hematopoietic stem cell transplant (HSCT). Despite undergoing HSCT, approximately 40% of acute myeloid leukemia (AML) patients relapse and face an extremely poor prognosis, with two-year survival rates of less than 20%. The traditional tumor target ... [Read more...]
| Industry Biotechnology | IPO Date Feb 5, 2021 |
| CEO Robert Ang, M.B.B.S. | Employees 92 |
| Stock Exchange NASDAQ | Ticker Symbol VOR |